Kymera Therapeutics

KYMR57

$47.02arrow_drop_up4.49%$2.02

KYMR57

$47.02

arrow_drop_up4.49%$2.02

Performance History

Key Stats
Open	$45.41
Prev. Close	$44.98
EPS	-2.34
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	44.98	48.24
52 Week Range	9.60	53.55

Ratios







EPS	-2.34

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Kymera Therapeutics (KYMR)

Kymera Therapeutics, Inc. (KYMR) is a biotechnology company focused on advancing the field of targeted protein degradation. The company utilizes its proprietary platform to develop small molecule therapeutics that selectively degrade disease-causing proteins. By targeting specific proteins for degradation, Kymera aims to provide innovative and more effective treatments for a wide range of diseases, including cancer, autoimmune disorders, and inflammatory conditions.

The history of Kymera Therapeutics dates back to its founding in 2016 by a team of experienced scientists and drug developers. Since its inception, the company has made significant progress in advancing its pipeline and establishing valuable partnerships with leading pharmaceutical companies. Kymera's approach to targeted protein degradation has attracted the attention of investors and industry experts, resulting in successful fundraising efforts and recognition within the biotech community.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Nello Mainolfi M.D., Ph.D.
Headquarters: Watertown
Employees: 181
Exchange: NASDAQ

Keep an eye on Kymera Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Kymera Therapeutics's (KYMR) price per share?

The current price per share for Kymera Therapeutics (KYMR) is $47.02. The stock has seen a price change of $2.02 recently, indicating a 4.49% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Kymera Therapeutics (KYMR)?

For Kymera Therapeutics (KYMR), the 52-week high is $53.55, which is 13.89% from the current price. The 52-week low is $9.6, the current price is 389.79% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Kymera Therapeutics (KYMR) a growth stock?

Kymera Therapeutics (KYMR) has shown an average price growth of -3.36% over the past three years. It has received a score of 70 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Kymera Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Kymera Therapeutics (KYMR) stock price performance year to date (YTD)?

As of the latest data, Kymera Therapeutics (KYMR) has a year-to-date price change of 85.48%. Over the past month, the stock has experienced a price change of -2.02%. Over the last three months, the change has been -5.49%. Over the past six months, the figure is 40.23%.

help

Is Kymera Therapeutics (KYMR) a profitable company?

Kymera Therapeutics (KYMR) has a net income of -$146.96M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.93K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $78.59M, with a revenue growth rate of 67.84%, providing insight into the company's sales performance and growth. Operating income is noted at -$165.53M. Furthermore, the EBITDA is -$190.49M.

help

What is the market capitalization of Kymera Therapeutics (KYMR)?

Kymera Therapeutics (KYMR) has a market capitalization of $3.05B. The average daily trading volume is 47.13, indicating the stock's liquidity and investor engagement.